12/16
09:50 am
crnx
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $87.00 price target on the stock.
Low
Report
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $87.00 price target on the stock.
12/16
08:07 am
crnx
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer [Yahoo! Finance]
12/16
08:00 am
crnx
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
Low
Report
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
12/10
08:44 pm
crnx
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/9
08:00 am
crnx
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
Medium
Report
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
11/15
09:00 am
crnx
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
Medium
Report
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
11/14
04:17 pm
crnx
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting [Yahoo! Finance]
Medium
Report
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting [Yahoo! Finance]
11/14
04:05 pm
crnx
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Medium
Report
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
11/14
02:38 pm
crnx
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Citigroup Inc. from $70.00 to $74.00. They now have a "buy" rating on the stock.
Medium
Report
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Citigroup Inc. from $70.00 to $74.00. They now have a "buy" rating on the stock.
11/14
08:02 am
crnx
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) [Yahoo! Finance]
11/13
02:43 pm
crnx
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at HC Wainwright from $69.00 to $81.00. They now have a "buy" rating on the stock.
Low
Report
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at HC Wainwright from $69.00 to $81.00. They now have a "buy" rating on the stock.
11/13
02:26 am
crnx
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/12
04:08 pm
crnx
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/12
04:07 pm
crnx
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Low
Report
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
11/12
04:05 pm
crnx
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
11/11
04:05 pm
crnx
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/16
08:00 am
crnx
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
Medium
Report
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
10/10
04:40 pm
crnx
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/9
01:21 am
crnx
Crinetics Pharmaceuticals prices $500M equity at $50 per share [Seeking Alpha]
Medium
Report
Crinetics Pharmaceuticals prices $500M equity at $50 per share [Seeking Alpha]
10/8
11:55 pm
crnx
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Medium
Report
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
10/8
04:01 pm
crnx
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Low
Report
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
9/27
11:05 am
crnx
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $80.00 price target on the stock.
Low
Report
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $80.00 price target on the stock.
9/26
04:05 pm
crnx
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
Low
Report
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly